Tesamorelin + Ipamorelin Stack
| Category | Stacks |
|---|---|
| Also known as | Tesa Ipa, VAT Reduction Stack |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | stackgrowth-hormoneghrhvisceral-fatmetabolic |
Overview
The Tesamorelin + Ipamorelin Stack combines Tesamorelin — an FDA-approved GHRH analog with documented effects on visceral adipose tissue — with Ipamorelin, a selective ghrelin receptor agonist.
Tesamorelin is unique among the GHRH analogs discussed in research because it has a substantial body of human clinical data, including approval for HIV-associated lipodystrophy. The molecule has the same active sequence as native GHRH(1-44) with a stabilizing N-terminal trans-3-hexenoyl moiety that extends half-life. Pairing it with Ipamorelin brings the same GHRH + GHRP synergy that defines this class of stacks.
Compounds in This Stack
- Tesamorelin — Stabilized GHRH(1-44) analog with FDA approval for visceral adiposity reduction.
- Ipamorelin — Selective ghrelin receptor agonist with minimal cortisol or prolactin elevation.
Rationale
Tesamorelin engages the GHRH receptor and is well-documented for reducing visceral adipose tissue in clinical populations. The mechanism is presumed to be growth hormone-mediated lipolysis, with downstream IGF-1 elevation. Ipamorelin adds the ghrelin receptor arm, suppressing somatostatin tone and releasing the brake on GH secretion.
The stack is conceptually similar to other GHRH + GHRP combinations but is distinguished by Tesamorelin's clinical track record. Researchers often choose this pairing when the metabolic — particularly visceral fat — endpoint is the primary focus.
Research Context
| Component | Distinguishing Feature |
|---|---|
| Tesamorelin | FDA-approved, clinical VAT reduction data |
| Ipamorelin | Clean GH pulse without cortisol/prolactin |
Tesamorelin's clinical literature provides far more human pharmacology data than other GHRH analogs in the research-supply space.
Typical Research Parameters
Tesamorelin is typically administered once daily in clinical settings, often pre-bedtime to align with natural GH pulses. Ipamorelin is administered separately, often two to three times daily. Observation windows of twelve to twenty-six weeks are common when visceral adipose tissue is the primary endpoint, since changes accumulate slowly.
Considerations
Because Tesamorelin has robust clinical data, the safety and tolerability profile is well-characterized — injection site reactions are the most common observation. Adding Ipamorelin extends the GH stimulation pattern but introduces the typical considerations of GHRP administration, including the importance of timing relative to meals. The stack is research-only outside of the FDA-approved Tesamorelin indication.
Related Stacks
- CJC-1295 + Ipamorelin Stack
- [Sermorelin + GHRP-2 Stack](/wiki/sermorelin-ghrp-2-stack)
- MOD-GRF + Ipamorelin Stack
- MOTS-c + Tesamorelin Stack
- [Hexarelin + CJC-1295 Stack](/wiki/hexarelin-cjc-1295-stack)
Related Compounds
Related entries
- Ipamorelin— A selective growth hormone secretagogue pentapeptide that stimulates GH release from the pituitary with minimal effects on cortisol, prolactin, and appetite compared to other GHRPs.
- Tesamorelin— A synthetic growth hormone-releasing hormone (GHRH) analog approved by the FDA for reduction of excess abdominal fat in HIV-associated lipodystrophy, also studied for cognitive and metabolic applications.